PUBLISHER: Grand View Research | PRODUCT CODE: 1553533
PUBLISHER: Grand View Research | PRODUCT CODE: 1553533
U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2024 - 2030
U.S. Contraceptive Market Growth & Trends:
The U.S. contraceptive market size is anticipated to reach USD 12.46 billion by 2030 and is projected to grow at a CAGR of 5.20% from 2024 - 2030, according to a new report by Grand View Research, Inc. The growing availability of contraceptives in the United States has positively influenced various societal aspects, including education, career opportunities, and poverty levels among women. Access to modern contraceptive methods has significantly enhanced women's career prospects, enabling them to earn wages comparable to their male counterparts. In addition, it has resulted in a decrease in the number of women experiencing poverty due to unplanned pregnancies and the financial burdens associated with raising children.
The legalization and access to family planning services have contributed to reducing poverty and improving economic conditions for future generations. Family planning programs have been linked to improved health outcomes for women and children, which indirectly support economic stability. Women who can control their reproductive health are more likely to participate in the workforce and contribute to household income, further reducing poverty levels.
In June 2023, The Biden-Harris Administration launched a new public-private partnership between the U.S. Department of Health and Human Services (HHS) to enhance access to contraception, which is a crucial aspect of reproductive health. This initiative seeks to tackle the increasing disparities in women's health across the United States. The Biden-Harris Administration is committed to enhancing international family planning efforts, particularly in West Africa, where contraceptive use is low and maternal mortality rates are high. An additional USD 15.5 million has been allocated for fiscal year 2023, bringing the total to USD 86.5 million aimed at improving sexual and reproductive health care in nine Francophone countries.
Furthermore, the COVID-19 pandemic has significantly impacted the U.S. healthcare sector. Contraceptive manufacturers, such as Merck & Co., reported a reduction in demand for the contraceptive implant Nexplanon due to the prioritization of COVID-19 patients by healthcare providers. However, an increase in vaccination and reduced burden of COVID-19 patients helped restore the physician office visits for contraceptive administration, in turn contributing to product demand. Demand for long-acting and nonhormonal contraceptives is expected to increase in the coming years due to convenience, long-term protection, and fewer side effects demonstrated by these contraceptives.
U.S. Contraceptive Market Report Highlights:
- In terms of product, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products.
- The operations of market players are affected by generic competition, industry consolidation, competitive combination products, new information from clinical trials of marketed products, and patents granted to competitors' new products, among others.
- The demand for nonhormonal contraceptives in young women is expected to increase as they want to avoid risks associated with hormonal contraceptives. Newly developed products, such as nonhormonal vaginal rings, diaphragms, and innovative condoms, are expected to aid the growth of nonhormonal products segment during the forecast period.
- In April 2024, the Opill U.S. FDA approved the first oral contraceptive OTC pill, which began selling at most stores in retail pharmacies such as Walgreens, CVS, and Walmart. The product is also offered at CVS Pharmacy app and CVS.com and more than 7,500 CVS Pharmacy stores in the U.S.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Estimates and Forecast Timeline
- 1.2. Market Definitions
- 1.2.1. Segment definitions
- 1.2.1.1. Product
- 1.2.1. Segment definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.4.1. Details of Primary Research
- 1.4.5. Research Assumption
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Data Visualization
- 1.7. Model Details
- 1.7.1. Approach 1: Commodity flow analysis
- 1.7.2. Approach 2: Volume Price Analysis
- 1.8. Objectives
- 1.8.1. Objective - 1
- 1.8.2. Objective - 2
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.2.1. Product
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.1.1. Rapid technological advancements
- 3.3.1.2. Increasing initiatives by social organizations to improve access to condoms
- 3.3.1.3. Rising publicly funded family planning services
- 3.3.2. Market Restraint Analysis
- 3.3.2.1. Increasing geriatric population and rising prevalence of infertility
- 3.3.2.2. Adverse effects associated with use of contraceptive drugs and devices
- 3.3.3. Industry Opportunities
- 3.3.4. Industry Challenges
- 3.3.1. Market Driver Analysis
- 3.4. Regulatory and Reimbursement Framework
- 3.5. Pipeline Analysis
- 3.6. Impact of COVID-19: Qualitative Analysis
- 3.7. Business Environment Analysis Tools
- 3.7.1. Industry Analysis - Porter's Five Forces Analysis
- 3.7.1.1. Supplier power
- 3.7.1.2. Buyer power
- 3.7.1.3. Substitution threat
- 3.7.1.4. Threat of new entrant
- 3.7.1.5. Competitive rivalry
- 3.7.2. PESTEL Analysis
- 3.7.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. U.S. Contraceptive Market, By Product, 2018 - 2030 (USD Million)
- 4.1. U.S. Contraceptive Market: Product Segment Dashboard
- 4.2. Product Movement & Market Share Analysis, 2023 & 2030
- 4.3. U.S. Contraceptive Market Size & Forecast and Forecasts, By Product, 2018 - 2030 (USD Million)
- 4.4. Pills
- 4.4.1. Pills market, 2018 - 2030 (USD Million)
- 4.4.2. Intrauterine Device (IUD)
- 4.4.2.1. Intrauterine Device (IUD) market, 2018 - 2030 (USD Million)
- 4.4.2.2. Hormonal IUD
- 4.4.2.2.1. Hormonal IUD market, 2018 - 2030 (USD Million)
- 4.4.2.3. Nonhormonal IUD
- 4.4.2.3.1. Nonhormonal IUD market, 2018 - 2030 (USD Million)
- 4.5. Condoms
- 4.5.1. Condoms market, 2018 - 2030 (USD Million)
- 4.5.2. Male Condoms
- 4.5.2.1. Male condoms market, 2018 - 2030 (USD Million)
- 4.5.2.2. Female condoms
- 4.5.2.2.1. Female condoms market, 2018 - 2030 (USD Million)
- 4.6. Vaginal Ring
- 4.6.1. Vaginal ring market, 2018 - 2030 (USD Million)
- 4.7. Subdermal Implants
- 4.7.1. Subdermal implants market, 2018 - 2030 (USD Million)
- 4.8. Injectable
- 4.8.1. Injectable market, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Others market, 2018 - 2030 (USD Million)
Chapter 5. Competitive Landscape
- 5.1. Recent Developments & Impact Analysis, by Key Market Participants
- 5.2. Major Deals & Strategic Alliances Analysis
- 5.2.1. Mergers & acquisitions and joint ventures
- 5.2.2. Licensing & partnership and technology collaborations
- 5.3. Vendor Landscape
- 5.3.1. List of Players in the U.S. Contraceptive Market
- 5.3.2. Company Market Position Analysis
- 5.4. Participant's overview
- 5.5. Financial Performance
- 5.6. Product Benchmarking
- 5.7. Company Categorization
- 5.8. Company Market Position Analysis
- 5.9. Strategy Mapping
- 5.9.1. Expansion
- 5.9.2. Acquisition
- 5.9.3. Collaborations
- 5.9.4. Others
- 5.10. Company Profiles/Listing
- 5.10.1. Church & Dwight Co., Inc.
- 5.10.1.1. Overview
- 5.10.1.2. Financial Performance
- 5.10.1.3. Product Benchmarking
- 5.10.1.4. Strategic Initiatives
- 5.10.2. Reckitt Benckiser Group plc
- 5.10.2.1. Overview
- 5.10.2.2. Financial Performance
- 5.10.2.3. Product Benchmarking
- 5.10.2.4. Strategic Initiatives
- 5.10.3. Veru, Inc.
- 5.10.3.1. Overview
- 5.10.3.2. Financial Performance
- 5.10.3.3. Product Benchmarking
- 5.10.3.4. Strategic Initiatives
- 5.10.4. Organon Group of Companies
- 5.10.4.1. Overview
- 5.10.4.2. Financial Performance
- 5.10.4.3. Product Benchmarking
- 5.10.4.4. Strategic Initiatives
- 5.10.5. Pfizer, Inc.
- 5.10.5.1. Overview
- 5.10.5.2. Financial Performance
- 5.10.5.3. Product Benchmarking
- 5.10.5.4. Strategic Initiatives
- 5.10.6. Teva Pharmaceutical Industries Ltd.
- 5.10.6.1. Overview
- 5.10.6.2. Financial Performance
- 5.10.6.3. Product Benchmarking
- 5.10.6.4. Strategic Initiatives
- 5.10.7. The Cooper Companies, Inc.
- 5.10.7.1. Overview
- 5.10.7.2. Financial Performance
- 5.10.7.3. Product Benchmarking
- 5.10.7.4. Strategic Initiatives
- 5.10.8. Mayer Laboratories, Inc.
- 5.10.8.1. Overview
- 5.10.8.2. Financial Performance
- 5.10.8.3. Product Benchmarking
- 5.10.8.4. Strategic Initiatives
- 5.10.9. Agile Therapeutics
- 5.10.9.1. Overview
- 5.10.9.2. Financial Performance
- 5.10.9.3. Product Benchmarking
- 5.10.9.4. Strategic Initiatives
- 5.10.10. TherapeuticsMD, Inc.
- 5.10.10.1. Overview
- 5.10.10.2. Financial Performance
- 5.10.10.3. Product Benchmarking
- 5.10.10.4. Strategic Initiatives
- 5.10.11. Bayer AG
- 5.10.11.1. Overview
- 5.10.11.2. Financial Performance
- 5.10.11.3. Product Benchmarking
- 5.10.11.4. Strategic Initiatives
- 5.10.12. Afaxys, Inc.
- 5.10.12.1. Overview
- 5.10.12.2. Financial Performance
- 5.10.12.3. Product Benchmarking
- 5.10.12.4. Strategic Initiatives
- 5.10.13. Mithra Pharmaceuticals
- 5.10.13.1. Overview
- 5.10.13.2. Financial Performance
- 5.10.13.3. Product Benchmarking
- 5.10.13.4. Strategic Initiatives
- 5.10.14. Abbvie
- 5.10.14.1. Overview
- 5.10.14.2. Financial Performance
- 5.10.14.3. Product Benchmarking
- 5.10.14.4. Strategic Initiatives
- 5.10.1. Church & Dwight Co., Inc.
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 Contraceptive methods and associated side effects
- Table 4 Classification of contraceptives by the U.S. FDA
- Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
- Table 6 Types of oral contraceptives, composition, and regimen
- Table 7 List of intrauterine devices currently available in the U.S.
- Table 8 Types of male condom variants
- Table 9 US contraceptive market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 U.S. contraceptive market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Market snapshot
- Fig. 10 Segment snapshot
- Fig. 11 Competitive landscape
- Fig. 12 U.S. contraceptive market: Parent market outlook
- Fig. 13 U.S. contraceptive market dynamics
- Fig. 14 Market driver relevance analysis (Current & future impact)
- Fig. 15 Market restraint relevance analysis (Current & future impact)
- Fig. 16 U.S. contraceptive market: Porter's five forces analysis
- Fig. 17 U.S. contraceptive market: PESTLE analysis
- Fig. 18 U.S. contraceptive market: product segment dashboard
- Fig. 19 U.S. contraceptive market: product market share analysis, 2023 & 2030
- Fig. 20 Pills market, 2018 - 2030 (USD Million)
- Fig. 21 Intrauterine Devices (IUD) market, 2018 - 2030 (USD Million)
- Fig. 22 Hormonal IUD market, 2018 - 2030 (USD Million)
- Fig. 23 Nonhormonal IUD market, 2018 - 2030 (USD Million)
- Fig. 24 Condoms market, 2018 - 2030 (USD Million)
- Fig. 25 Male condoms market, 2018 - 2030 (USD Million)
- Fig. 26 Female condoms market, 2018 - 2030 (USD Million)
- Fig. 27 Vaginal ring market, 2018 - 2030 (USD Million)
- Fig. 28 Subdermal implants market, 2018 - 2030 (USD Million)
- Fig. 29 Injectable market, 2018 - 2030 (USD Million)
- Fig. 30 Others market, 2018 - 2030 (USD Million)
- Fig. 31 Company/competition categorization
- Fig. 32 Company market position analysis
- Fig. 33 U.S. contraceptive market: Strategy mapping
